Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.


Heathcote R Wright, PhD FRANZCO
Hugh R Taylor, AC, MD
Emily O'Kearney, MIPH, BPhty
Section Editor
Peter F Weller, MD, MACP
Deputy Editor
Elinor L Baron, MD, DTMH


Trachoma is a contagious eye infection caused by Chlamydia trachomatis and is the leading infectious cause of blindness worldwide. C. trachomatis is transmitted by intimate social or sexual contact. Serotypes A, B, Ba, and C cause trachoma, and serotypes D to K cause genital tract infection. (See "Clinical manifestations and diagnosis of Chlamydia trachomatis infections" and "Treatment of Chlamydia trachomatis infection".)


Trachoma is endemic in over 42 countries [1]. It is generally confined to resource-limited settings in developing nations of Africa, the Middle East, Asia, Latin America, Pacific Islands, and remote Aboriginal communities in Australia (figure 1) [1]. Worldwide, over 200 million people live in trachoma-endemic areas and 7.2 million live with advanced trachoma [1].

Active infection with C. trachomatis is mostly seen in young children with a peak incidence around four to six years, while subsequent scarring and blindness are seen in adults (figure 2). In many regions, women have two to six times the rate of trachoma than men [2,3], which may be due to women's ongoing exposure to children with C. trachomatis infection [4].

Transmission — Trachoma is spread by direct contact with eye, nose, and throat secretions from affected individuals (figure 3). It can also be spread by contact with fomites such as handkerchiefs, towels, or washcloths contaminated with these secretions. Eye-seeking flies such as Musca sorbens can carry C. trachomatis, but there is no animal or insect reservoir [5,6].

Survey assessment — Since most patients with active trachoma are asymptomatic and are young children (figure 2), survey methods are needed to identify populations at risk. The choice of a survey method must take into account the anticipated trachoma prevalence and concerns specific to a local community. Population-based surveys remain the gold standard for determining prevalence and for establishing and monitoring intervention programs. Rapid assessment protocols also have an important role.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Mar 22, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Trachoma Atlas. http://www.trachomaatlas.org/ (Accessed on August 29, 2016).
  2. Schwab L, Whitfield R Jr, Ross-Degnan D, et al. The epidemiology of trachoma in rural Kenya. Variation in prevalence with lifestyle and environment. Study Survey Group. Ophthalmology 1995; 102:475.
  3. West S, Nguyen MP, Mkocha H, et al. Gender equity and trichiasis surgery in the Vietnam and Tanzania national trachoma control programmes. Br J Ophthalmol 2004; 88:1368.
  4. Turner VM, West SK, Muñoz B, et al. Risk factors for trichiasis in women in Kongwa, Tanzania: a case-control study. Int J Epidemiol 1993; 22:341.
  5. Miller K, Pakpour N, Yi E, et al. Pesky trachoma suspect finally caught. Br J Ophthalmol 2004; 88:750.
  6. Wilson M, Keyvan-Larijani E, Millan-Velasco F, et al. The epidemiology of trachoma in Chiapas (Mexico). Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique 1987; :159.
  7. Negrel AD, Taylor HR, West S. Guidelines for the rapid assessment for blinding trachoma. World Health Organization and International Trachoma Initiative, Geneva 2001. http://www.who.int/blindness/TRA-ENGLISH.pdf (Accessed on October 27, 2016).
  8. Negrel AD, Mariotti SP. Trachoma rapid assessment: rationale and basic principles. Community Eye Health 1999; 12:51.
  9. Myatt M, Limburg H, Minassian D, Katyola D. Field trial of applicability of lot quality assurance sampling survey method for rapid assessment of prevalence of active trachoma. Bull World Health Organ 2003; 81:877.
  10. Myatt M, Mai NP, Quynh NQ, et al. Using lot quality-assurance sampling and area sampling to identify priority areas for trachoma control: Viet Nam. Bull World Health Organ 2005; 83:756.
  11. Solomon AW, Zondervan, M, Kuper H, et al. Trachoma control: A guide for programme managers. World Health Organization, Geneva 2006. http://apps.who.int/iris/bitstream/10665/43405/1/9241546905_eng.pdf (Accessed on October 27, 2016).
  12. Taylor HR, Siler JA, Mkocha HA, et al. The natural history of endemic trachoma: a longitudinal study. Am J Trop Med Hyg 1992; 46:552.
  13. Thylefors B, Dawson CR, Jones BR, et al. A simple system for the assessment of trachoma and its complications. Bull World Health Organ 1987; 65:477.
  14. Taylor HR, West SK, Katala S, Foster A. Trachoma: evaluation of a new grading scheme in the United Republic of Tanzania. Bull World Health Organ 1987; 65:485.
  15. Mabey DC, Solomon AW, Foster A. Trachoma. Lancet 2003; 362:223.
  16. Solomon AW, Peeling RW, Foster A, Mabey DC. Diagnosis and assessment of trachoma. Clin Microbiol Rev 2004; 17:982.
  17. West SK, Muñoz B, Mkocha H, et al. Progression of active trachoma to scarring in a cohort of Tanzanian children. Ophthalmic Epidemiol 2001; 8:137.
  18. Bobo LD, Novak N, Muñoz B, et al. Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection. J Infect Dis 1997; 176:1524.
  19. Dawson CR, Jones BR, Darougar S. Blinding and non-blinding trachoma: assessment of intensity of upper tarsal inflammatory disease and disabling lesions. Bull World Health Organ 1975; 52:279.
  20. Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004; 351:1962.
  21. Wright HR, Taylor HR. Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us? Lancet Infect Dis 2005; 5:313.
  22. de Barbeyrac B, Goldschmidt P, Malembic S, et al. Quality assessment of conjunctival specimens for detection of Chlamydia trachomatis by PCR in children with active trachoma. Clin Microbiol Infect 2007; 13:689.
  23. Martin DL, Bid R, Sandi F, et al. Serology for trachoma surveillance after cessation of mass drug administration. PLoS Negl Trop Dis 2015; 9:e0003555.
  24. Mariotti SP. New steps toward eliminating blinding trachoma. N Engl J Med 2004; 351:2004.
  25. Amza A, Goldschmidt P, Einterz E, et al. Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops. PLoS Negl Trop Dis 2010; 4:e895.
  26. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993; 342:453.
  27. Dawson CR, Schachter J, Sallam S, et al. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis 1997; 24:363.
  28. Tabbara KF, Abu-el-Asrar A, al-Omar O, et al. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 1996; 103:842.
  29. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet 1999; 354:630.
  30. Fraser-Hurt N, Bailey RL, Cousens S, et al. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ 2001; 79:632.
  31. Chern KC, Shrestha SK, Cevallos V, et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br J Ophthalmol 1999; 83:1332.
  32. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 1997; 24:356.
  33. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis 2013; 56:1519.
  34. Gaynor BD, Holbrook KA, Whitcher JP, et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br J Ophthalmol 2003; 87:147.
  35. Yorston D, Mabey D, Hatt S, Burton M. Interventions for trachoma trichiasis. Cochrane Database Syst Rev 2006; :CD004008.
  36. Reacher MH, Huber MJ, Canagaratnam R, Alghassany A. A trial of surgery for trichiasis of the upper lid from trachoma. Br J Ophthalmol 1990; 74:109.
  37. Adamu Y, Alemayehu W. A randomized clinical trial of the success rates of bilamellar tarsal rotation and tarsotomy for upper eyelid trachomatous trichiasis. Ethiop Med J 2002; 40:107.
  38. Bowman RJ, Faal H, Jatta B, et al. Longitudinal study of trachomatous trichiasis in The Gambia: barriers to acceptance of surgery. Invest Ophthalmol Vis Sci 2002; 43:936.
  39. West S, Lynch M, Munoz B, et al. Predicting surgical compliance in a cohort of women with trichiasis. Int Ophthalmol 1994; 18:105.
  40. Oliva MS, Munoz B, Lynch M, et al. Evaluation of barriers to surgical compliance in the treatment of trichiasis. Int Ophthalmol 1997-1998; 21:235.
  41. Burton MJ, Kinteh F, Jallow O, et al. A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia. Br J Ophthalmol 2005; 89:1282.
  42. Reacher MH, Muñoz B, Alghassany A, et al. A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch Ophthalmol 1992; 110:667.
  43. Reacher M, Foster A, Huber J. Trichiasis surgery for trachoma: the bilamellar tarsal rotation procedure. World Health Organization, Geneva 1998. http://apps.who.int/iris/bitstream/10665/62064/1/WHO_PBL_93.29.pdf (Accessed on October 27, 2016).
  44. Barr K, Essex RW, Liu S, Henderson T. Comparison of trichiasis recurrence after primary bilamellar tarsal rotation or anterior lamellar repositioning surgery performed for trachoma. Clin Exp Ophthalmol 2014; 42:311.
  45. Bog H, Yorston D, Foster A. Results of community-based eyelid surgery for trichiasis due to trachoma. Br J Ophthalmol 1993; 77:81.
  46. Bowman RJ, Jatta B, Faal H, et al. Long-term follow-up of lid surgery for trichiasis in the Gambia: surgical success and patient perceptions. Eye (Lond) 2000; 14:864.
  47. Khandekar R, Mohammed AJ, Courtright P. Recurrence of trichiasis: a long-term follow-up study in the Sultanate of Oman. Ophthalmic Epidemiol 2001; 8:155.
  48. Thanh TT, Khandekar R, Luong VQ, Courtright P. One year recurrence of trachomatous trichiasis in routinely operated Cuenod Nataf procedure cases in Vietnam. Br J Ophthalmol 2004; 88:1114.
  49. Burton MJ, Bowman RJ, Faal H, et al. Long term outcome of trichiasis surgery in the Gambia. Br J Ophthalmol 2005; 89:575.
  50. West S, Alemayehu W, Munoz B, Gower EW. Azithromycin prevents recurrence of severe trichiasis following trichiasis surgery: STAR trial. Ophthalmic Epidemiol 2007; 14:273.
  51. Zhang H, Kandel RP, Atakari HK, Dean D. Impact of oral azithromycin on recurrence of trachomatous trichiasis in Nepal over 1 year. Br J Ophthalmol 2006; 90:943.
  52. Woreta F, Munoz B, Gower E, et al. Three-year outcomes of the surgery for trichiasis, antibiotics to prevent recurrence trial. Arch Ophthalmol 2012; 130:427.
  53. West SK, West ES, Alemayehu W, et al. Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. Arch Ophthalmol 2006; 124:309.
  54. Kocak-Midillioglu I, Akova YA, Koçak-Altintas AG, et al. Penetrating keratoplasty in patients with corneal scarring due to trachoma. Ophthalmic Surg Lasers 1999; 30:734.
  55. Yorston D, Wood M, Foster A. Penetrating keratoplasty in Africa: graft survival and visual outcome. Br J Ophthalmol 1996; 80:890.
  56. al-Rifai KM. Trachoma through history. Int Ophthalmol 1988; 12:9.
  57. Habtamu E, Rajak SN, Tadesse Z, et al. Epilation for minor trachomatous trichiasis: four-year results of a randomised controlled trial. PLoS Negl Trop Dis 2015; 9:e0003558.
  58. Kuper H, Solomon AW, Buchan J, et al. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis 2003; 3:372.
  59. West SK, Munoz B, Mkocha H, et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 2005; 366:1296.
  60. Burton MJ, Holland MJ, Faal N, et al. Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci 2003; 44:4215.
  61. Atik B, Thanh TT, Luong VQ, et al. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA 2006; 296:1488.
  62. West ES, Munoz B, Mkocha H, et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci 2005; 46:83.
  63. Evans JR, Solomon AW. Antibiotics for trachoma. Cochrane Database Syst Rev 2011; :CD001860.
  64. Porco TC, Gebre T, Ayele B, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009; 302:962.
  65. Gebre T, Ayele B, Zerihun M, et al. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet 2012; 379:143.
  66. Solomon AW, Harding-Esch E, Alexander ND, et al. Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med 2008; 358:1870.
  67. Keenan JD, Ayele B, Gebre T, et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clin Infect Dis 2012; 54:253.
  68. Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med 1999; 5:572.
  69. Melese M, Chidambaram JD, Alemayehu W, et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA 2004; 292:721.
  70. Gill DA, Lakew T, Alemayehu W, et al. Complete elimination is a difficult goal for trachoma programs in severely affected communities. Clin Infect Dis 2008; 46:564.
  71. Melese M, Alemayehu W, Lakew T, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 2008; 299:778.
  72. Amza A, Kadri B, Nassirou B, et al. A Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma Treatment to Children. Clin Infect Dis 2017; 64:743.
  73. House JI, Ayele B, Porco TC, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial. Lancet 2009; 373:1111.
  74. See CW, O'Brien KS, Keenan JD, et al. The Effect of Mass Azithromycin Distribution on Childhood Mortality: Beliefs and Estimates of Efficacy. Am J Trop Med Hyg 2015; 93:1106.
  75. Taylor HR, West SK, Mmbaga BB, et al. Hygiene factors and increased risk of trachoma in central Tanzania. Arch Ophthalmol 1989; 107:1821.
  76. Hsieh YH, Bobo LD, Quinn TC, West SK. Risk factors for trachoma: 6-year follow-up of children aged 1 and 2 years. Am J Epidemiol 2000; 152:204.
  77. West S, Muñoz B, Lynch M, et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet 1995; 345:155.
  78. Ejere HO, Alhassan MB, Rabiu M. Face washing promotion for preventing active trachoma. Cochrane Database Syst Rev 2015; :CD003659.
  79. Hamilton H, Velleman Y. WASHing away blinding trachoma. Sightsavers, West Sussex, UK 2013. http://www.who.int/blindness/causes/WASHing_away_blinding_trachoma.pdf (Accessed on August 29, 2016).
  80. Taylor HR. A Blinding Scourge from the Bronze Age to the Twenty-first Century, Centre for Eye Research Australia, Melbourne 2008.
  81. Stocks ME, Ogden S, Haddad D, et al. Effect of water, sanitation, and hygiene on the prevention of trachoma: a systematic review and meta-analysis. PLoS Med 2014; 11:e1001605.
  82. West S, Lynch M, Turner V, et al. Water availability and trachoma. Bull World Health Organ 1989; 67:71.
  83. West SK, Emerson PM, Mkocha H, et al. Intensive insecticide spraying for fly control after mass antibiotic treatment for trachoma in a hyperendemic setting: a randomised trial. Lancet 2006; 368:596.
  84. Emerson PM, Lindsay SW, Alexander N, et al. Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial. Lancet 2004; 363:1093.